The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Efficacy of Aromatase Inhibitors Combined with Growth Hormone Therapy in Male Adolescents with Idiopathic Short Stature

  • By

  • Yiling Cui

  • Qiting Zhang

  • Ling Hou

  • Xiaoping Luo

  • May 6, 2025

Share

  • 1

    The study evaluated the efficacy of aromatase inhibitors combined with growth hormone therapy in male adolescents with idiopathic short stature.

  • 2

    Adolescent boys treated with anastrozole and rhGH showed the most significant increase in adult height compared to letrozole and GnRHa groups.

  • 3

    The combination of aromatase inhibitors and rhGH significantly increased adult height in adolescents with idiopathic short stature and advanced bone age.

  • 4

    Adverse reactions in the aromatase inhibitors group returned to normal after treatment cessation, indicating a favorable safety profile.

  • 5

    The findings support the clinical application of aromatase inhibitors in treating male adolescents with idiopathic short stature.

Original Source(s)

The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents

  • by Yiling Cui, Qiting Zhang, Ling Hou, Xiaoping Luo

  • May 6, 2025

Related Content

AHA Updates Diet Guidance, Highlights Plant Shift

Revised American Heart Association statement urges a shift toward plant-based protein and flags ongoing uncertainty in fat and alcohol recommendations.

Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.

Glycemic variability may signal retinal changes

Greater glucose fluctuations but not HbA1c were associated with neuroretinal alterations over 3 years in pediatric patients with type 1 diabetes.